Stryker Launches Mako RPS Handheld Robotics for Total Knee

What happened

Stryker has announced the U.S. commercial launch of Mako RPS, a handheld robotic power system for total knee replacement, expanding the Mako platform beyond traditional robotic-arm assisted surgery. This new technology targets a broader segment of the orthopedic market by offering a more accessible, portable solution for robotic-assisted knee procedures. While the launch strengthens Stryker's robotics moat and could drive higher implant attach rates, the DeepValue report continues to flag the stock as a Potential Sell due to its rich valuation at ~46x P/E and ~30x EV/EBITDA. The report highlights limited margin of safety, integration risks from recent acquisitions (e.g., Inari), and tariff headwinds that could compress multiples if growth disappoints. Bothered investors should monitor Mako adoption metrics and attach rates to gauge whether this innovation can sustain the premium valuation.

Implication

If Mako RPS drives accelerated attach rates and procedure volume growth, it could support Stryker's above-market growth narrative and partially justify its premium multiple. However, the deep value report's thesis of overvaluation (DCF ~$124 vs. ~$352) and risks from tariffs, acquisition integration, and competitive pressure (Zimmer ROSA, J&J Velys) remain intact. Sustained double-digit sales growth and margin expansion are needed to avoid multiple compression, making this a show-me story for long-term investors.

Thesis delta

The Mako RPS launch incrementally strengthens Stryker's robotics moat and could drive higher implant attach rates, supporting the company's high-end MedTech growth strategy. However, it does not address the core valuation concern: the stock trades at ~46x P/E with minimal margin of safety against a DCF value of ~$124/share. The thesis shifts slightly more positive on fundamentals but remains cautious on price, as any disappointment in adoption or margins could trigger significant de-rating.